IL-23 Archives - Medical Conferences

ICONIC-LEAD in plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 3, ICONIC-LEAD

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:49

Improving efficacy with longer mirikizumab treatment in CD

Presented By

Prof. Séverine Vermeire, KU Leuven, Belgium

Trial

Phase 3, VIVID-2

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:39

Latest data for subcutaneous guselkumab in CD and UC

Presented By

Prof. Ailsa Hart, London North-West University, UK; Prof. Laurent Peyrin-Biroulet, University of Lorraine, France

Trial

Phase 3, GRAVITI, ASTRO

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:31

Sustained efficacy and stable safety profile for risankizumab in UC

Presented By

Prof. Raja Atreya, Friedrich-Alexander University, Germany

Trial

Phase 3, COMMAND

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:08

Risankizumab influences key pathogenic Th17 cells in CD

Presented By

Dr Daniele Noviello, University of Milan, Italy

Trial

SEQUENCE

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:23

PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

PsoBest registry

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:23

Advanced therapies show promising results in PsA real-world study

Presented By

Prof. Dennis McGonagle, University of Leeds, UK

Trial

PRO-SPIRIT

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:38

How close are we to personalised medicine in psoriatic arthritis?

Presented By

Prof. Ennio Lubrano, University of Molise, Ital

Conference

IFPA 2024

Type

News article

17 July 2024 14:38

Depression complicates the management of psoriatic disease

Presented By

Dr Wiebke Sondermann, University Hospital Essen, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:20

The unfavourable role of obesity in psoriatic disease

Presented By

Prof. Ulrich Mrowietz, University Medical Center Schleswig-Holstein, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:13

Multiple novel oral agents show promise in psoriasis

Presented By

Prof. April Armstrong, University of California Los Angeles, USA

Trial

FRONTIER; STRIDE

Conference

IFPA 2024

17 July 2024 14:04

Biologics for psoriasis: towards oral therapies and less frequent dosing

Presented By

Prof. Bruce Strober, Yale University, CT, USA

Trial

LIMMItless; GUIDE; FRONTIER

Conference

IFPA 2023

Type

News article

17 July 2024 14:00

GALAXI 2 & 3: Guselkumab proves efficacy in Crohn’s disease

Presented By

Dr Remo Panaccione, University of Calgary, Canada

Trial

GALAXI

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 13:01

QUASAR maintenance study: Guselkumab effective and safe for UC

Presented By

Dr David Rubin, University of Chicago, USA

Trial

QUASAR

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 12:58

GUIDE demonstrates: Hit hard and early in psoriasis

Presented By

Prof. Knut Schäkel, University Clinic Heidelberg, Germany

Trial

Phase 3, GUIDE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:36

Durable skin clearance by IL-23 blockers due to reduction of resident memory T cells

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:41

Meet the Trialist: Dr Andrew Blauvelt on the KNOCKOUT Trial

Expert

Dr Andrew Blauvelt

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

22 April 2024 12:12

VIVID-1: Mirikizumab meets expectations in Crohn’s disease

Presented By

Prof. Marc Ferrante, University Hospitals Leuven, Belgium

Trial

Phase 3, VIVID-1

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:49

COMMAND: Long-term efficacy benefits of risankizumab in ulcerative colitis

Presented By

Prof. Stefan Schreiber, University Hospital Schleswig-Holstein, Germany

Trial

Phase 3, COMMAND

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:47

SEQUENCE: Risankizumab versus ustekinumab across endpoints

Presented By

Prof. Marla Dubinsky, Mount Sinai Hospital, NY, USA

Trial

Phase 3, SEQUENCE

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:45

QUASAR: Guselkumab improves QoL for patients with ulcerative colitis

Presented By

Prof. Julian Panés, Hospital Clinic de Barcelona, Spain

Trial

Phase 3, QUASAR

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:43

Fatigue, urgency, and QoL improvements on mirikizumab in Crohn’s disease

Presented By

Prof. Simon Travis, University of Oxford, UK

Trial

Phase 3, VIVID-1

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:41

SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD

Presented By

Prof. Laurent Peyrin-Biroulet, University Hospital of Nancy, France

Trial

Phase 3, SEQUENCE

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:44

Guselkumab provides benefits in UC regardless of advanced therapy history

Presented By

Prof. Axel Dignass, Goethe University, Germany

Trial

Phase 3, QUASAR

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:42

INSPIRE: Risankizumab meets all efficacy endpoints in UC

Presented By

Prof. Edouard Louis, Liège University Hospital, Belgium

Trial

Phase 3, INSPIRE

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:39

Drug survival of guselkumab and risankizumab seems superior to other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:04

IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis

Presented By

Prof. Bruce Strober, Yale University School of Medicine, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:01

First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 2, FRONTIER 1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:57

Encouraging results for first oral IL-23 receptor antagonist in plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 2, FRONTIER 1

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:35

Knocking out psoriasis with high-dose risankizumab?

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 2, KNOCKOUT

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:30

Ulcerative colitis: bowel urgency remission associated with improvement in fatigue

Presented By

Dr David Rubin, University of Chicago, IL, USA

Trial

Phase 3, LUCENT-1, LUCENT-2

Conference

DDW 2023

Type

News article

13 June 2023 13:52

Favourable maintenance rates for risankizumab also in delayed responders with CD

Presented By

rof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 3, FORTIFY

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:56

IL-23 inhibition reduces inflammatory biomarkers in pre-treated UC

Presented By

Prof. Julian Panés, Hospital Clínic Barcelona, Spain

Trial

Phase 2, QUASAR

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:53

Maintained symptom control with mirikizumab in UC

Presented By

Prof. Axel Dignass, Agaplesion Markus Hospital, Germany

Trial

Phase 3, LUCENT 2

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:49

Mirikizumab successfully resolves active histologic inflammation in UC

Presented By

Prof. Fernando Magro, CHU de São João, Portugal

Trial

Phase 2, LUCENT 2

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:44

Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

KEEPsAKE 1; KEEPsAKE 2

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:28

IL-23 inhibition beneficial in maintenance treatment of UC

Presented By

Prof. Marla C. Dubinsky, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, LUCENT-2

Conference

DDW 2022

Type

News article

14 June 2022 22:01

Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease

Presented By

Dr Neeraj Narula, McMaster University, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:46

Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis

Presented By

Prof. Remo Panaccione , University of Calgary, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:44

Guselkumab shows encouraging safety and efficacy in ulcerative colitis

Presented By

Prof. Axel Dignass, Agaplesion Markus Hospital, Germany

Trial

Phase 2, QUASAR Induction

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:23

Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 2, GALAXI-1

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:21

Mirikizumab efficacious for active ulcerative colitis

Presented By

Prof. Geert D’Haens, Amsterdam University Medical Center, the Netherlands

Trial

Phase 3, LUCENT-1

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:18

Risankizumab more efficacious in colonic than in ileal Crohn’s disease

Presented By

Dr Peter Bossuyt, Imelda General Hospital, Belgium

Trial

Phase 3, ADVANCE, MOTIVATE, FORTIFY

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:15

Guselkumab plus golimumab promising combination for ulcerative colitis

Presented By

Prof. Bruce Sands, Mount Sinai School of Medicine, NY, USA

Trial

Phase 2, VEGA

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:10

Potential biomarker discovered for treatment response to ustekinumab

Presented By

Mr Shane Solanky, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 15:46

Explaining arthropathy development through IL-4 and IL-13 blockade

Presented By

Dr Charlie Bridgewood, University of Leeds, UK

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 10:51

Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion

Presented By

Dr Ali Al-Janabi, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:22

Selective IL-23 inhibition normalises gene expression in active PsA

Presented By

Ms Michelle Miron

Trial

Phase 3, DISCOVER-1&-2

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 13:48

Selective IL-23 inhibition: a new option in active PsA

Presented By

Prof. Andrew Östör, Monash University, Australia

Trial

Phase 3, KEEPsAKE 1, KEEPsAKE 2

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:52

Existing and upcoming small molecules in psoriasis

Presented By

Dr Enikö Sonkoly , Karolinska University Hospital, Sweden

Trial

POETYK PSO; PSOARING

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:19

Risankizumab meets primary endpoints in maintenance study for CD patients

Presented By

Prof. Marc Ferrante, University Hospital Leuven, Belgium

Trial

Phase 3, FORTIFY

Conference

UEGW 2021

Type

News article

27 October 2021 10:11

Psoriatic arthritis: Guidelines and best practice

Trial

Phase 3, BE ACTIVE, PATERA

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 11:19

Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on

Presented By

Prof. April W. Armstrong, University of Southern California, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:32

Convincingly low levels of infections with long-term tildrakizumab

Trial

reSURFACE 1 and 2

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:15

Selective IL-23 blocker shows potential in psoriasis treatment

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 3, OASIS-2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:44

Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease

Principal Investigator

Prof. Bruce E. Sands, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 2, SERENITY

Conference

UEGW 2020

Type

News article

2 November 2020 12:20

Selective IL-23 blocker safe in elderly psoriasis patients

Presented By

Prof. Peter van de Kerkhof, Radboudumc, the Netherlands

Trial

reSURFACE

Conference

AAD 2020

Type

Peer-reviewed article

19 August 2020 13:18

ECLIPSE trial: skin clearance independent of PsA status at baseline

Presented By

Prof. Kristian Reich

Trial

Phase 3, ECLIPSE

Conference

AAD 2020

Type

Peer-reviewed article

7 August 2020 13:12

Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis

Presented By

Prof. Richard B. Warren

Trial

IMMerge

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:07

Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?

Presented By

Dr Nikolai Klebanov , Brigham and Women’s Hospital, USA

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 07:01

Lowest risk of infection after therapy with an IL-12/IL-23 blocker

Presented By

Dr Yinzhu Jin, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA

Trial

Cohort study

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:42

Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis

Presented By

Prof. Atul Deodhar, Oregon Health & Science University, USA

Trial

Phase 3, DISCOVER

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 19:53

Phase 2 data shows benefit for mirikizumab in CD patients

Presented By

Prof. Bruce Sands, Icahn School of Medicine at Mount Sinai, New York, USA

Conference

UEGW 2019

Type

Peer-reviewed article

23 October 2019 19:42

Novel selective IL-23 blocker equally effective in patients with metabolic syndrome

Presented By

Dr Alice Gottlieb, Tufts University School of Medicine, USA

Trial

reSURFACE 1 and 2

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 17:28

Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 16:30

New targets and biologics for cutaneous lupus erythematosus

Presented By

Prof. Victoria P. Werth, University of Pennsylvania, USA

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 15:59

Novel selective IL-23 blocker highly effective over 2 years

Trial

Phase 3, IMMhance

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 11:52

Biologicals beyond TNF blockade

Presented By

Prof. Brian Kirby, St. Vincent’s University Hospital, Ireland

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 11:11

Registries – an important research tool in biologics

Presented By

Prof. Bruce E. Strober, UConn Health, USA

Conference

WCD 2019

Type

Peer-reviewed article

26 August 2019 10:10

Advances in target-oriented therapy: psoriatic arthritis

Presented By

Prof. Wolf-Henning Boehncke, University of Geneva, Switzerland

Trial

ECLIPSA, TICOPA

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 23:48

Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis

Presented By

Prof. Jonathan Barker, Kings College London, United Kingdom

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 20:34

Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?

Presented By

Prof. Kristian Reich, Georg-August-University Göttingen, Germany

Trial

ECLIPSE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 18:23

Small molecules, apremilast, and TYK2

Presented By

Prof. Richard Langley, Dalhousie University, Canada

Trial

ESTEEM, PALACE, LIBERATE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 09:45

Molecular effects of ustekinumab

Trial

Phase 3, UNITI

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 19:47

p19-Directed IL-23 antibody mirikizumab

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 19:26

Moving towards new therapeutic options

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 14:44

Plaque psoriasis – Efficacy of guselkumab

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 20:06

Psoriasis and Biologics: The Beat Goes On

Presented By

Prof. Mark Lebwohl, Mount Sinai School of Medicine, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 14:06

Central role of IL-23 in molecular resistance to anti-TNF therapy

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 21:06